Loring Wolcott & Coolidge Fiduciary Advisors’s Core Laboratories CLB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-275
| Closed | -$8K | – | 726 |
|
|
2021
Q3 | $8K | Hold |
275
| – | – | ﹤0.01% | 612 |
|
|
2021
Q2 | $11K | Buy |
+275
| New | +$9.86K | ﹤0.01% | 615 |
|
|
2021
Q1 | – | Sell |
-275
| Closed | -$7K | – | 383 |
|
|
2020
Q4 | $7K | Hold |
275
| – | – | ﹤0.01% | 631 |
|
|
2020
Q3 | $4K | Hold |
275
| – | – | ﹤0.01% | 549 |
|
|
2020
Q2 | $6K | Hold |
275
| – | – | ﹤0.01% | 526 |
|
|
2020
Q1 | $3K | Sell |
275
-12,863
| -98% | -$360K | ﹤0.01% | 602 |
|
|
2019
Q4 | $495K | Hold |
13,138
| – | – | 0.01% | 207 |
|
|
2019
Q3 | $612K | Sell |
13,138
-990
| -7% | -$46K | 0.01% | 186 |
|
|
2019
Q2 | $739K | Sell |
14,128
-8,075
| -36% | -$474K | 0.01% | 173 |
|
|
2019
Q1 | $1.53M | Sell |
22,203
-8,685
| -28% | -$582K | 0.02% | 130 |
|
|
2018
Q4 | $1.84M | Buy |
30,888
+4,015
| +15% | +$346K | 0.03% | 115 |
|
|
2018
Q3 | $3.11M | Sell |
26,873
-2,773
| -9% | -$313K | 0.05% | 105 |
|
|
2018
Q2 | $3.74M | Sell |
29,646
-1,490
| -5% | -$181K | 0.07% | 97 |
|
|
2018
Q1 | $3.37M | Sell |
31,136
-1,775
| -5% | -$196K | 0.06% | 103 |
|
|
2017
Q4 | $3.6M | Sell |
32,911
-1,325
| -4% | -$132K | 0.07% | 102 |
|
|
2017
Q3 | $3.38M | Hold |
34,236
| – | – | 0.07% | 101 |
|
|
2017
Q2 | $3.44M | Sell |
34,236
-17,065
| -33% | -$1.84M | 0.07% | 101 |
|
|
2017
Q1 | $5.93M | Hold |
51,301
| – | – | 0.12% | 86 |
|
|
2016
Q4 | $6.16M | Sell |
51,301
-420
| -0.8% | -$46.5K | 0.14% | 86 |
|
|
2016
Q3 | $5.81M | Sell |
51,721
-525
| -1% | -$60.5K | 0.13% | 87 |
|
|
2016
Q2 | $6.47M | Sell |
52,246
-25
| -0% | -$3.02K | 0.15% | 81 |
|
|
2016
Q1 | $5.88M | Sell |
52,271
-2
| -0% | -$208 | 0.14% | 85 |
|
|
2015
Q4 | $5.68M | Sell |
52,273
-950
| -2% | -$109K | 0.14% | 87 |
|
|
2015
Q3 | $6.07M | Hold |
53,223
| – | – | 0.15% | 80 |
|
|
2015
Q2 | $6.07M | Buy |
53,223
+1,725
| +3% | +$209K | 0.15% | 80 |
|
|
2015
Q1 | $5.38M | Sell |
51,498
-200
| -0.4% | -$21.3K | 0.14% | 86 |
|
|
2014
Q4 | $6.22M | Sell |
51,698
-126
| -0.2% | -$16.6K | 0.16% | 84 |
|
|
2014
Q3 | $7.58M | Sell |
51,824
-445
| -0.9% | -$68.7K | 0.21% | 75 |
|
|
2014
Q2 | $8.73M | Sell |
52,269
-534
| -1% | -$95K | 0.24% | 69 |
|
|
2014
Q1 | $10.5M | Sell |
52,803
-2,495
| -5% | -$471K | 0.29% | 64 |
|
|
2013
Q4 | $10.6M | Sell |
55,298
-2,325
| -4% | -$433K | 0.29% | 60 |
|
|
2013
Q3 | $9.75M | Hold |
57,623
| – | – | 0.3% | 63 |
|
|
2013
Q2 | $8.74M | Buy |
+57,623
| New | +$8.16M | 0.27% | 68 |
|
Other funds holding CLB
AI
FAM
DGI
Loring Wolcott & Coolidge Fiduciary Advisors's CLB Position: Q4 2021 in Review
Loring Wolcott & Coolidge Fiduciary Advisors sold out of Core Laboratories (CLB) in Q4 2021, closing a stake of 275 shares — an estimated $8K sold.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in CLB in Q2 2013 and held it in 33 quarters. The position peaked at $10.6M in Q4 2013. 174 funds tracked by Wall St. Rank hold CLB as of Q4 2021.
- Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Core Laboratories position as of Q4 2021 after selling out during the quarter.
- Loring Wolcott & Coolidge Fiduciary Advisors sold 275 Core Laboratories shares in Q4 2021, an estimated $8K.
- Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Core Laboratories in Q2 2013 and held it in 33 quarters.
- Loring Wolcott & Coolidge Fiduciary Advisors's Core Laboratories position peaked at $10.6M in Q4 2013.
- 174 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2021.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.